Synthesis of antiplasmodial 2-aminothieno[3,2-d]pyrimidin-4(3H)-one analogues using the scaffold hopping strategy.


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
05 Nov 2022
Historique:
received: 16 06 2022
revised: 15 07 2022
accepted: 17 07 2022
pubmed: 26 7 2022
medline: 2 9 2022
entrez: 25 7 2022
Statut: ppublish

Résumé

Gamhepathiopine (also known as M1), is a multi-stage acting antiplasmodial 2-tert-butylaminothieno[3,2-d]pyrimidin-4(3H)-one hydrochloride that was first described in 2015. The development of this compound is limited by poor microsomal stability, insufficient aqueous solubility and low intestinal permeability. In order to obtain new optimized derivatives, we conducted a scaffold hopping strategy from compound M1, resulting in the synthesis of 20 new compounds belonging to six chemical series. All the compounds were tested on the K1 multi-resistant strain of Plasmodium falciparum and the human HepG2 cell-line, to evaluate their antiplasmodial activity and their cytotoxicity. Analogues' biological results also highlighted the mandatory presence of a heteroatom at position 5 of the thieno[3,2-d]pyrimidin-4(3H)-one moeity for the antiplasmodial activity. However, modifications at position 7 were detrimental for the antiplasmodial activity. We identified furane bioisostere 3j as a promising candidate, showing good blood stage antiplasmodial activity, better water solubility and highly improved intestinal permeability in the PAMPA assay.

Identifiants

pubmed: 35872545
pii: S0223-5234(22)00521-9
doi: 10.1016/j.ejmech.2022.114619
pii:
doi:

Substances chimiques

Antimalarials 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114619

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Auteurs

Romain Mustière (R)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France.

Prisca Lagardère (P)

Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier, France.

Sébastien Hutter (S)

Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.

Viviana Dell'Orco (V)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France.

Nadia Amanzougaghene (N)

Centre d'Immunologie et des Maladies Infectieuses (CIMI), INSERM, CNRS, Sorbonne Université, Paris, France.

Shahin Tajeri (S)

Centre d'Immunologie et des Maladies Infectieuses (CIMI), INSERM, CNRS, Sorbonne Université, Paris, France.

Jean-François Franetich (JF)

Centre d'Immunologie et des Maladies Infectieuses (CIMI), INSERM, CNRS, Sorbonne Université, Paris, France.

Sophie Corvaisier (S)

Normandie Univ, Unicaen, CERMN, Caen, France.

Marc Since (M)

Normandie Univ, Unicaen, CERMN, Caen, France.

Aurélie Malzert-Fréon (A)

Normandie Univ, Unicaen, CERMN, Caen, France.

Nicolas Masurier (N)

Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier, France.

Vincent Lisowski (V)

Institut des Biomolécules Max Mousseron, UMR 5247, CNRS, Université de Montpellier, ENSCM, UFR des Sciences Pharmaceutiques et Biologiques, Montpellier, France.

Pierre Verhaeghe (P)

CHU de Nîmes, Service de pharmacie, Nimes, France; LCC-CNRS, Université de Toulouse, CNRS UPR 8241, UPS, Toulouse, France.

Dominique Mazier (D)

Centre d'Immunologie et des Maladies Infectieuses (CIMI), INSERM, CNRS, Sorbonne Université, Paris, France.

Nadine Azas (N)

Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.

Patrice Vanelle (P)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France; Service Central de la Qualité et de l'Information Pharmaceutiques, APHM, Hôpital Conception, Marseille, France.

Nicolas Primas (N)

Aix Marseille Univ, CNRS, ICR UMR 7273, Equipe Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Marseille, France; Service Central de la Qualité et de l'Information Pharmaceutiques, APHM, Hôpital Conception, Marseille, France. Electronic address: nicolas.primas@univ-amu.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH